Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
PHP Toggle Menu

Category: BT-001

Transgene’s and BioInvent’s BT-001 achieves outstanding tumor cure rates in preclinical models

20200622b – BT-001_AACR poster EN

Published 22 June 2020
Categorized as 2020, BT-001, Invir.IO, Press release

Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020

20200622a – Transgene PR AACR 3 posters

Published 22 June 2020
Categorized as 2020, BT-001, Invir.IO, Myvac, Press release

Transgene and BioInvent present preclinical data demonstrating BT-001’s powerful activity against solid tumors

20200515 BT-001_AACR curtain raiser EN

Published 15 May 2020
Categorized as 2020, BT-001, Invir.IO, Press release

BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment

Poster BT-001Marchand, Semmrich, Fend et al. Immuno-Oncology summit Download the poster here Poster Presentation

Published 11 March 2020
Categorized as 2020, BT-001, Publication

Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses

20200303 BT-001 presentations EN

Published 3 March 2020
Categorized as 2020, BT-001, Press release

Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors

20191211 PR preclinical BT001 EN

Published 11 December 2019
Categorized as 2019, BT-001, Invir.IO, Press release

Posts pagination

Newer posts Page 1 … Page 4
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
Menu